Cilag

Janssen Seeks Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Retrieved on: 
Monday, January 20, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Medicine, Clinical medicine, Johnson & Johnson, Tyrosine kinase inhibitors, Breakthrough therapy, Cancer treatments, Acrylamides, Ibrutinib, Janssen Pharmaceutica, Cilag, Chemotherapy, ibrutinib, chronic lymphocytic leukaemia, the Janssen Pharmaceutical Companies of Johnson & Johnson

We look forward to working with regulatory authorities to bring ibrutinib to more patients with CLL who may benefit from treatment.

Key Points: 
  • We look forward to working with regulatory authorities to bring ibrutinib to more patients with CLL who may benefit from treatment.
  • We remain committed to replacing long-standing use of chemotherapy with ibrutinib-based combination regimens for the treatment of patients with CLL in the frontline setting.
  • Patients are often prescribed multiple lines of therapy as they relapse or become resistant to treatments.
  • Janssen-Cilag and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Saturday, December 7, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Johnson & Johnson, Medicine, Companies, Health, Chimeric antigen receptor T cell, Cilag, Janssen Pharmaceutica, B-cell maturation antigen, Janssen, Takeda Oncology, CARTITUDE-1, LEGEND-2, JNJ-68284528 (LCAR-B38M), CAR-T and BCMA, Multiple Myeloma, the Janssen Pharmaceutical Companies of Johnson & Johnson

Safety and efficacy results observed in the CARTITUDE-1 study were consistent with the LEGEND-2 study of LCAR-B38M, sponsored by Legend Biotech.

Key Points: 
  • Safety and efficacy results observed in the CARTITUDE-1 study were consistent with the LEGEND-2 study of LCAR-B38M, sponsored by Legend Biotech.
  • In December 2017, Janssen entered into an exclusive worldwide license and collaboration agreement with Legend to develop and commercialise JNJ-68284528/LCAR-B38M.
  • Cilag GmbH International; Janssen Biotech, Inc.; Janssen Oncology, Inc. and Janssen-Cilag International NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1).

Janssen Reports Top-Line Phase 3 Results for TREMFYA® (guselkumab) in Adults with Active Psoriatic Arthritis

Retrieved on: 
Friday, June 14, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Johnson & Johnson, Monoclonal antibodies, Companies, Organ systems, Health, Cilag, Janssen Pharmaceutica, Guselkumab, Ustekinumab, Psoriasis, Janssen, Pharmaceutical industry

The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to TREMFYA which is currently approved in the US, Canada and the EU.

Key Points: 
  • The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to TREMFYA which is currently approved in the US, Canada and the EU.
  • For complete EU prescribing and safety information, please visit: https://www.medicines.org.uk/emc/medicine/34321
    At Janssen, were creating a future where disease is a thing of the past.
  • Janssen-Cilag International NV, the marketing authorisation holder for TREMFYA in the EU, and Janssen Research & Development, LLC, are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Retrieved on: 
Friday, March 22, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Research, Science, Drugs, Medicine, Clinical medicine, Orphan drugs, Immunosuppressants, Cancer treatments, Monoclonal antibodies, RTT, Daratumumab, Lenalidomide, Multiple myeloma, Cilag

The randomised, open-label, multicentre Phase 3 study included 737 newly diagnosed patients with multiple myeloma ineligible for high-dose chemotherapy and ASCT aged 45-90 years old (median age of 73 years).

Key Points: 
  • The randomised, open-label, multicentre Phase 3 study included 737 newly diagnosed patients with multiple myeloma ineligible for high-dose chemotherapy and ASCT aged 45-90 years old (median age of 73 years).
  • Janssen Biotech, Inc., Janssen-Cilag International NV, and Janssen-Cilag Limited are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA).
  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Janssen to Showcase New Data Across Broad Rheumatology Portfolio and Immunology Pipeline at EULAR 2018

Retrieved on: 
Monday, June 11, 2018
Monoclonal antibodies, Immunology, Anatomy, Immunosuppressants, Janssen Biotech, Ustekinumab, Medicine, Janssen, Rheumatology, Systemic lupus erythematosus, Cilag

Data from the rheumatology portfolio includes latest research findings on Stelara (ustekinumab), an anti-interleukin (IL)-12/23 monoclonal antibody, in the treatment of active systemic lupus erythematosus (SLE)*.

Key Points: 
  • Data from the rheumatology portfolio includes latest research findings on Stelara (ustekinumab), an anti-interleukin (IL)-12/23 monoclonal antibody, in the treatment of active systemic lupus erythematosus (SLE)*.
  • [3],[4],[5]
    "At Janssen we are committed to addressing the unmet needs of people living with rheumatic diseases today and in the future.
  • We're looking forward to presenting the latest data from our portfolio and pipeline at this prestigious conference," comments Wim Noel, Medical Affairs Director Rheumatology, EMEA at Janssen-Cilag NV.
  • Stelara is a registered trademark of Janssen Biotech, Inc.
    For complete European Union (EU) prescribing information, please visit: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info... .